Skip to main content
. 2016 May 11;24(1):55–64. doi: 10.3727/096504016X14586627440192

Figure 1.

Figure 1

Erlotinib suppresses glucose consumption in HNSCC cells. (A) Glucose concentrations in the cell culture media of FaDu, Cal-27, SCC-25, and SQ20B HNSCC cells were measured before and after 24 h DMSO (CON) or erlotinib (ERL) treatment. (B, C) SCC-25 cells were treated with DMSO or ERL for 24 and 48 h then analyzed for PKM2 mRNA levels by RT-PCR (B) and protein levels by Western blot (C). (D, E) FaDu cells were treated with DMSO or ERL, and glucose concentrations (D) and clonogenic survival (E) were measured 24, 48, and 72 h after treatment. Glucose concentrations were normalized to cell number. NSF, normalized surviving fraction. Error bars represent ± standard error of the mean (SEM) of at least N = 3 experiments. *p < 0.05 versus DMSO.